Exscientia (NASDAQ:EXAI) Shares Gap Down to $5.05

Exscientia plc (NASDAQ:EXAI) shares gapped down before the market opened on Monday . The stock had previously closed at $5.05, but opened at $4.93. Exscientia shares last traded at $4.75, with a volume of 354,401 shares traded.

Wall Street Analyst Weigh In

Several brokerages recently commented on EXAI. TD Cowen reaffirmed a “hold” rating on shares of Exscientia in a research note on Friday. Morgan Stanley reiterated an “equal weight” rating and set a $7.00 target price on shares of Exscientia in a report on Monday, April 22nd. Finally, Barclays lowered their price target on Exscientia from $10.00 to $9.00 and set an “overweight” rating for the company in a research report on Monday, July 29th.

Exscientia Stock Performance

The company has a market capitalization of $577.84 million, a PE ratio of -3.85 and a beta of 0.85. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.30 and a current ratio of 6.30. The business’s 50-day moving average is $5.26 and its 200-day moving average is $5.42.

Exscientia (NASDAQ:EXAI) last released its earnings results on Tuesday, May 21st. The company reported ($0.21) EPS for the quarter. The company had revenue of $6.70 million during the quarter. Exscientia had a negative return on equity of 34.59% and a negative net margin of 666.80%. On average, research analysts anticipate that Exscientia plc will post -1.12 earnings per share for the current year.

Institutional Trading of Exscientia

Large investors have recently made changes to their positions in the stock. Private Advisor Group LLC increased its position in Exscientia by 114.3% during the fourth quarter. Private Advisor Group LLC now owns 22,500 shares of the company’s stock valued at $144,000 after acquiring an additional 12,000 shares during the last quarter. Raymond James Financial Services Advisors Inc. purchased a new position in shares of Exscientia in the fourth quarter worth approximately $207,000. Jump Financial LLC grew its position in Exscientia by 47.7% during the fourth quarter. Jump Financial LLC now owns 53,755 shares of the company’s stock valued at $345,000 after buying an additional 17,355 shares during the period. Walled Lake Planning & Wealth Management LLC purchased a new stake in Exscientia during the fourth quarter valued at approximately $64,000. Finally, New Republic Capital LLC bought a new position in Exscientia in the fourth quarter worth approximately $128,000. 41.58% of the stock is currently owned by institutional investors.

Exscientia Company Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.